Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,305.12 +58.44 (+1.11%) Dow
39,887.37 +329.26 (+0.83%) Nasdaq
16,740.68 +229.50 (+1.39%) Bitcoin USD
66,254.65 +4,673.25 (+7.59%) CMC Crypto 200
1,390.48 +122.54 (+9.67%)
OLMA Jun 2024 10.000 put
| Previous close | 1.9100 |
| Open | 1.9100 |
| Bid | 0.0000 |
| Ask | 1.6500 |
| Strike | 10.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.9100 - 1.9100 |
| Contract range | N/A |
| Volume | |
| Open interest | 65 |
GlobeNewswireOlema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWI
- GlobeNewswire
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to be presented at the ESMO Breast Cancer Annual Congress 2024 in Berlin, Germany. Olema will host an investor conference call on May 15, 2024, at 8:00 a.m. ET to review the dataInvestigational New Drug (IND) application for OP-3136, a novel KAT6 inhibitor, expected to be filed with FDA in late 2024Ca
- GlobeNewswire
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will present new clinical data from the Company’s ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibit
